Recent developments in ghrelin receptor (GHS-R1a) agonists and antagonists

Expert Opinion on Therapeutic Patents

Volumn 12, Issue 11, 2002, Pages 1599-1618

  Carpino, Philip A ^a  

^a PFIZER INC   (United States)

Author keywords

Cachexia; First generation GHSs; Frailty; Ghrelin; GHS R1a antagonists; Growth hormone (GH); Growth hormone secretagogue (GHS); Growth hormone secretagogue receptor type 1a (GHS R1a); Growth hormone releasing peptides (GHRPs); Obesity; Partial GHS R1a agoniss

Indexed keywords

3 AMINO 3 METHYL N [2,3,4,5 TETRAHYDRO 2 OXO 1 [[2' (1H TETRAZOL 5 YL) 1,1' BIPHENYL 4 YL]METHYL] 1H 1 BENZAZEPIN 3 YL]BUTANAMIDE; ADENOSINE DERIVATIVE; CAPROMORELIN; G 7134; G PROTEIN COUPLED RECEPTOR; GHRELIN; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; GROWTH HORMONE SECRETAGOGUE; GROWTH HORMONE SECRETAGOGUE RECEPTOR; HEXARELIN; HORMONE DERIVATIVE; HORMONE RECEPTOR BLOCKING AGENT; HORMONE RECEPTOR STIMULATING AGENT; IBUTAMOREN; IPAMORELIN; L 166446; L 692400; L 756867; LY 444711; NNC 26 1089; NNC 26 1167; OXINDOLE; PEPTIDE HORMONE; PRALMORELIN; QUINAZOLINE DERIVATIVE; SM 130686; SOMATOMEDIN C; TABIMORELIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANOREXIA NERVOSA; APPETITE; BIOSYNTHESIS; BODY COMPOSITION; CACHEXIA; CARDIOMYOPATHY; DRUG SELECTIVITY; DRUG STRUCTURE; ENERGY BALANCE; EXPERIMENTAL MODEL; FOOD INTAKE; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE RELEASE; HORMONE SYNTHESIS; HUMAN; HYPOPHYSIS; HYPOTHALAMUS; LIPID METABOLISM; METABOLIC DISORDER; MUSCLE MASS; MUSCULOSKELETAL DISEASE; NEUROENDOCRINOLOGY; NONHUMAN; OBESITY; PROTEIN LOCALIZATION; RAT; RECEPTOR AFFINITY; REVIEW; STOMACH; TREATMENT FAILURE; WASTING SYNDROME; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 0036848562     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.12.11.1599     Document Type: Review

References (104)

1. KOJIMA M, HOSODA H, DATE Y et al.: Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature (1999) 402:656-660.
2. HOSODA H, KOJIMA M, MATSUO H, KANGAWA K: Ghrelin and des-acyl ghrelin: two major forms of rat ghrelin peptide in gastrointestinal tissue. Biochem. Biophys. Res. Commun. (2000) 279:909-913.
3. HOSODA H, KOJIMA M, MATSUO H et al.: Purification and characterization of rat des-Gln14-ghrelin, a second endogenous ligand for the growth hormone secretagogue receptor. J. Biol. Chem. (2000) 275:21995-22000.
4. ARIYASU H, TAKAYA K, TAGAMI T et al.: Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. J. Clin. Endocrinol. Met. (2001) 86:4753-4758.
5. DATE Y, KOJIMA M, HOSODA H et al.: Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology (2000) 141:4255-4261.
6. MORI K, YOSHIMOTO A, TAKAYA K et al.: Kidney produces a novel acylated peptide, ghrelin. FEBS Lett. (2000) 486:213-216.
7. HOWARD AD, FEIGHNER SD, CULLY DF et al.: A receptor in pituitary and hypothalamus that functions in growth hormone release. Science (1996) 273:974-977.
8. GNANAPAVAN S, KOLA B, BUSTIN SA et al.: The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J. Clin. Endocrinol. Metab. (2002) 87:2988-2991.
9. NAKAZATO M, MURAKAMI N, DATE Y et al.: A role for ghrelin in the central regulation of feeding. Nature (2001) 409:194-198.
10. WREN AM, SMALL CJ, WARD HL et al.: The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. Endocrinology (2000) 41:4325-4328.
11. WREN AM, SMALL CJ, ABBOTT CR et al.: Ghrelin causes hyperphagia and obesity in rats. Diabetes (2001) 50:2540-2547.
12. TSCHOP M, SMILEY DL, HEIMAN ML: Ghrelin induces adiposity in rodents. Nature (2000) 407:908-913.
13. DATE Y, NAKAZATO M, MURAKAMI N et al.: Ghrelin acts in the central nervous system to stimulate gastric acid secretion. Biochem. Biophys. Res. Commun. (2001) 280:904-907.
14. MASUDA Y, TANAKA T, INOMATA N et al.: Ghrelin stimulates gastric acid secretion and motility in rats. Biochem. Biophys. Res. Commun. (2000) 276: 905-908.
15. PEINO R, BALDELLI R, RODRIGUEZ-GARCIA J et al.: Ghrelin-induced growth hormone secretion in humans. Eur. J. Endocrinol. (2000) 143:R11-R14.
16. WREN AM, SEAL LJ, COHEN MA et al.: Ghrelin enhances appetite and increases food intake in humans. J. Clin. Endocrinol. Metab. (2001) 86:5992-5995.
17. ARVAT E, MACCARIO M, DI VITO L et al.: Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone. J. Clin. Endocrinol. Metab. (2001) 86:1169-1174.
18. HATAYA Y, AKAMIZU T, TAKAYA K et al.: A low dose of ghrelin stimulates growth hormone (GH) release synergistically with GH-releasing hormone in humans. J. Clin. Endocrinol. Metab. (2001) 86:4552-4555.
19. BROGLIO F, ARVAT E, BENSO A et al.: Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. J. Clin. Endocrinol. Metab. (2001) 86:5083-5086.
20. NAGAYA N, KOJIMA M, UEMATSU M et al.: Hemodynamic and hormonal effects of human ghrelin in healthy volunteers. Am. J. Physiol. (2001) 280:R1483-R1487.
21. KAMEGAI J, TAMURA H, SHIMIZU T et al.: Chronic central infusion of ghrelin increases hypothalamic neuropeptide Y and agouti-related protein mRNA levels and body weight in rats. Diabetes (2001) 50:2438-2443.
22. SHINTANI M, OGAWA Y, EBIHARA K et al.: Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway. Diabetes (2001) 50:227-232.
23. SCHWARTZ MW, WOODS SC, PORTE Jr. D, SEELEY RJ, BASKIN DG: Central nervous system control of food intake. Nature (2000) 404:661-671.
24. CUMMINGS DE, PURNELL JQ, FRAYO RS et al.: A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes (2001) 50:1714-1719.
25. TSCHOP M, WAWARTA R, RIEPL RL et al.: Post-prandial decrease of circulating human ghrelin levels. J. Endocrinol. Invest. (2001) 24:RC19-RC21.
26. ARIYASU H, TAKAYA K, TAGAMI T et al.: Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. J. Clin. Endocrinol. Metab. (2001) 86:4753-4758.
27. MULLER AF, LAMBERTS SW, JANSSEN JA et al.: Ghrelin drives GH secretion during fasting in man. Eur. J. Endocrinol. (2002) 146:203-207.
28. OTTO B, CUNTZ U, FRUEHAUF E et al.: Weight gain decreases elevated plasma ghrelin concentrations of patients with anorexia nervosa. Eur. J. Endocrinol. (2001) 145:R5-R9.
29. TSCHOP M, WEYER C, TATARANNI PA et al.: Circulating ghrelin levels are decreased in human obesity. Diabetes (2001) 50:707-709.
30. CUMMINGS DE, WEIGLE DS, FRAYO RS et al.: Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N. Engl. J. Med. (2002) 346:1623-1630.
31. HANSEN TK, DALL R, HOSODA H et al.: Weight loss increases circulating levels of ghrelin in human obesity. Clin. Endocrinol. (2002) 56:203-206.
32. JEFFERY PL, HERINGTON AC, CHOPIN LK: Expression and action of the growth hormone releasing peptide ghrelin and its receptor in prostate cancer cell lines. J. Endocrinol. (2002) 172:R7-R11.
33. VOLANTE M, ALLIA E, GUGLIOTTA P et al.: Expression of ghrelin and of the GH secretagogue receptor by pancreatic islet cells and related endocrine tumors. J. Clin. Endocrinol. Metab. (2002) 87:1300-1308.
34. PAPOTTI M, CASSONI P, VOLANTE M et al.: Ghrelin-producing endocrine tumors of the stomach and intestine. J. Clin. Endocrinol. Metab. (2001) 86:5052-5059.
35. JEFFERY PL, HERINGTON AC, CHOPIN LK: Expression and action of the growth hormone releasing peptide ghrelin and its receptor in prostate cancer cell lines. J. Endocrinol. (2002) 172:R7-R11.
36. CASSONI P, PAPOTTI M, GHE C et al. Identification, characterization, and biological activity of specific receptors for natural (ghrelin) and synthetic growth hormone secretagogues and analogs in human breast carcinomas and cell lines. J. Clin. Endocrinol. Metab. (2001) 86:1738-1745.
37. GHE C, CASSONI P, CATAPANO F et al.: The antiproliferative effect of synthetic peptidyl GH secretagogues in human CALU-1 lung carcinoma cells. Endocrinology (2002) 143:484-491.
38. WANG G, LEE H-M, ENGLANDER E, GREELEY GH:Ghrelin-not just another stomach hormone. Regul. Pept. (2002) 105:75-81.
39. MUCCIOLI G, TSCHOP M, PAPOTTI M, DEGHENGHI R, HEIMAN M, GHIGO E: Neuroendocrine and peripheral activities of ghrelin: implications in metabolism and obesity. Eur. J. Pharmacol. (2002) 440:235-254.
40. HORVATH TL, DIANO S, SOTONYI P, HEIMAN M, TSCHOP M: Minireview: ghrelin and the regulation of energy balance-a hypothalamic perspective. Endocrinology (2001) 142:4163-4169.
41. GIBNEY J, WALLACE JD, SPINKS T et al.: The effects of 10 years of recombinant human growth hormone (GH) in adult GH-deficient patients. J. Clin. Endocrinol. Metab. (1999) 84:2596-2602.
42. THORNER M, ROCHICCIOLI P, COLLE M et al.: Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient child during the first year of therapy. J. Clin. Endocrinol. Metab. (1996) 81:1189-1196.
43. GENTH-ZOTZ S, ZOTZ R, GEIL S et al.: Recombinant growth hormone therapy in patients with ischemic cardiomyopathy: effects on hemodynamics, left ventricular function, and cardiopulmonary exercise capacity. Circulation (1999) 99:18-21.
44. SCHAMBELAN M, MULLIGAN K, GRUNFELD C et al.: Recombinant human growth hormone in patients with HIV-associated wasting; a randomized, placebo-controlled trial. Ann. Intern. Med. (1996) 125:873-882.
45. WOLF SE, NICOLAI M, DAGENAIS G: Growth hormone treatment in catabolic states other than burns. Growth Horm. IGF Res. (1998) 8:117-119.
46. RUDMAN D, FELLER AG, NAGRAJ HS et al.: Effects of human growth hormone in men over 60 years old. N. Engl. J. Med. (1990) 323:1-6.
47. NAGAYA N, UEMATSU M, KOJIMA M et al.: Elevated circulating level of ghrelin in cachexia associated with chronic heart failure. Relationships between ghrelin and anabolic/catabolic factors. Circulation (2001) 104:2034-2038.
48. WISSE BE, FRAYO RS, SCHWARTZ MW, CUMMINGS DE: Reversal of cancer anorexia by blockade of central melanocortin receptors in rats. Endocrinology (2001) 142:3292-3301.
49. ASAKAWA A, INUI A, KAGA T et al.: Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin. Gastroenterology (2001) 120:337-345.
50. DEGHENGHI R, CANANZI MM, TORSELLO A et al.: GH-releasing activity of hexarelin, a new growth hormone releasing peptide, in infant and adult rats. Life Sci. (1994) 54:1321-1328.
51. BOWERS CY: GH releasing peptides-structure and kinetics. J. Pediatr. Endocrinol. (1993) 6:21-31.
52. RAUN K, HANSEN BS, JOHANSEN NL et al.: Ipamorelin, the first selective growth hormone secretagogue. Eur. J. Endocrinol. (1998) 139:552-561.
53. ELIAS KA, INGLE GS, BURNIER JP et al.: In vitro characterizations of four novel classes of growth hormone-releasing peptide. Endocrinology (1995) 12:5694-5699.
54. HANSEN BS, RAUN K, NIELSEN KK et al.: Pharmacological characterization of a new oral GH secretagogue, NN703. Eur. J. Endocrinol. (1999) 141:180-189.
55. PATCHETT AA, NARGUND RP, TATA JR et al.: Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. Proc. Natl. Acad. Sci. (1995) 92:7001-7005.
56. PAN LC, CARPINO PA, LEFKER BA et al.: Preclinical pharmacology of CP-424,391, an orally active pyrazolidinone-piperidine growth hormone secretagogue. Endocrine (2001) 14:121-132.
57. SMITH RG, CHENG K, SCHOEN WR et al.: A nonpeptidyl growth hormone secretagogue. Science (1993) 260:1640-1643.
58. DEAN DC, NARGUND RP, PONG S-S et al.: Development of a high specific activity sulfur-35-labeled sulfonamide radioligand that allowed the identification of a new growth hormone secretagogue receptor. J. Med. Chem. (1996) 39:1767-1770.
59. 125I-labelled ghrelin to membranes from human hypothalamus and pituitary gland. J. Endocrinol. Invest. (2001) 24:RC7-RC9.
60. SMITH RG, VAN DER PLOEG LHT, HOWARD AD et al.: Peptidomimetic regulation of growth hormone secretion. Endocr. Rev. (1997) 18:621-645.
61. AHNFELT-RONNE I, NOWAK J, OLSEN UB: Do growth hormone-releasing peptides act as ghrelin secretagogues? Endocrine (2001) 14:133-135.
62. GHIGO E, ARVAT E, GIORDANO R et al.: Biologic activities of growth hormone secretagogues in humans. Endocrine (2001) 14:87-93.
63. BOWERS CY, REYNOLDS GA, DURHAM D, BARRERA CM, PEZZOLI SS, THORNER MO: Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J. Clin. Endocrinol. Metab. (1990) 70:975-982.
64. YANG L, MORRIELLO G, PATCHETT AA et al.: 1-[2(R)-(2-Amino- 2-methylpropionylamino)- 3-(1H-indol-3-yl) propionyl]-3- benzylpiperidine-3( S)-carboxylic Acid Ethyl Ester (L-163,540):a potent, orally bioavailable, and short-duration growth hormone secretagogue. J. Med. Chem. (1998) 41:2439-2441.
65. JOHANSEN PB, NOWAK J, SKJAERBAEK C et al.: Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm. IGF Res. (1999) 9:106-113.
66. SVENSSON J, LALL S, DICKSON SL et al.: The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. J. Endocrinol. (2000) 165:569-577.
67. CELLA SG, CERRI CG, DANIEL S et al.: Sixteen weeks of hexarelin therapy in aged dogs: effects on the somatotropic axis, muscle morphology, and bone metabolism. J. Gerontol. A. Bio. Sci. Med. Sci. (1996) 51:B439-B447.
68. ANDERSEN NB, MALMLOF K, JOHANSEN PB et al.: The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Growth Horm. IGF Res. (2001) 11:266-272.
69. ISGAARD J, TIVESTEN A, FRIBERG P, BENGTSSON B-A:The role of the GH/IGF-I axis for cardiac function and structure. Horm. Metab. Res. (1999) 31:50-54.
70. TIVESTEN A, BOLLANO E, CAIDAHL K et al.: The growth hormone secretagogue hexarelin improves cardiac function in rats after experimental myocardial infarction. Endocrinology (2000) 141:60-66.
71. MACANDREW JT, ELLERY SS, PARRY MA, PAN LC, BLACK SC: Efficacy of a growth hormone-releasing peptide mimetic in cardiac ischemia/reperfusion injury. Eur. J. Pharmacol. (2001) 432:195-202.
72. KING MK, GAY DM, PAN LC et al.: Treatment with a growth hormone secretagogue in a model of developing heart failure. Effects on ventricular and myocyte function. Circulation (2001) 103:308-313.
73. TSCHOP M, STATNICK MA, SUTER TM, HEIMAN ML: GH-releasing peptide-2 increases fat mass in mice lacking NPY: indication for a crucial mediating role of hypothalamic agouti-related protein. Endocrinology (2002) 143:558-568.
74. LALL S, TUNG LYC, OHLSSON C, JANSSON J-O, DICKSON SL: Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues. Biochem. Biophys. Res. Commun. (2001) 280:132-138.
75. LARON Z, FRENKEL J, DEGHENGHI R, ANIN S, KLINGER B, SILBERGELD A: Intranasal administration of the GHRP hexarelin accelerates growth in short children. Clin. Endocrinol. (1995) 43:631-635.
76. MERICQ V, CASSORLA F, SALAZAR T et al.: Effects of eight months treatment with graded doses of a growth hormone (GH)-releasing peptide in GH-deficient children. J. Clin. Endocrinol. Metab. (1998) 83:2355-2360.
77. GHIGO E, ARVAT E, CAMANNI F: Orally active growth hormone secretagogues: state of the art and clinical perspectives. Ann. Med. (1998) 30:159-168.
78. CODNER E, CASSORLA F, TIULPAKOV AN et al.: Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children. Clin. Pharmacol. Ther. (2001) 70:91-98.
79. CHAPMAN IM, BACH MA, VAN CAUTER E et al.: Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretagogue (MK-677) in healthy elderly subjects. J. Clin. Endocrinol. Metab. (1996) 81:4249-4257.
80. BACH MA, CAMBRIA M: Growth hormone releasing peptides: growth studies. Curr. Opin. Endocrinol. Diabetes(1999) 6:100-105.
81. SVENSSON J, LONN L, JANSSON J-O et al.: Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. J. Clin. Endocrinol. Metab. (1998) 83:362-369.
82. MURPHY MG, BACH MA, PLOTKIN D et al.: Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. J. Bone Miner. Res. (1999) 14:1182-1188.
83. PAPADAKIS MA, GRADY D, BLACK D et al.: Growth hormone replacement in healthy older men improves body composition but not functional ability. Ann. Intern. Med. (1996) 124:708-716.
84. NARGUND RP, YE Z, TATA J et al.: L-166,446, a second generation growth hormone secretagogue. 222nd ACS National Meeting, Chicago, IL, USA (2001). MEDI-184.
85. SMITH RG, SUN Y, SMITH AGA et al.: Ghrelin and a new class of synthetic GH secretagogues (GHS) activate the GHS receptor through a different site than GHRP-6 and MK-0677. 222nd American Chemical Society (ACS) National Meeting, Chicago, IL, USA (2001). MEDI-182.
86. ANKERSEN M, NIELSEN KK, HANSEN TK et al.: Growth hormone secretagogues derived from NN703 with hydrazides at C-terminal. Eur. J. Med. Chem. (2000) 35:487-497.
87. ANDERSEN P, ANKERSEN M, JESSEN CU, LEHMAN SV: The synthesis of a GH-releasing compound NNC 26-1089. Org. Process Res. & Dev. (2002) 6:367-373.
88. HANSEN TK, ANKERSEN M, RAUN K, HANSEN BS: Highly potent growth hormone secretagogues:Hybrids of NN703 and ipamorelin. Bioorg. Med. Chem. Lett. (2001) 11:1915-1918.
89. JUNGHEIM LN: Imidazole-based growth hormone secretagogues: adventures encountered on the road to LY444711. 222nd American Chemical Society (ACS) National Meeting, Chicago, IL, USA (2001). MEDI-183.
90. SEYLER DE, DODGE JA, OSBORNE JJ et al.: Effect of growth hormone secretagogue LY444711 on IGF-1, growth hormone, and cortisol levels in beagle dogs after one and seven daily oral doses. Drug Dev. Res. (2000) 49:260-265.
91. YE Z, GAO Y, BAKSHI RK et al.: Modeling directed design and biological evaluation of quinazolinones as non-peptidic growth hormone secretagogues. Bioorg. Med. Chem. Lett. (2000) 10:5-8.
92. HUANG P, LOEW GH, FUNAMIZU H et al.: Rational design, discovery, and synthesis of a novel series of potent growth hormone secretagogues. J. Med. Chem. (2001) 44:4082-4091.
93. ANKERSEN M, JOHANSEN NL, MADSEN K et al.: A new series of highly potent growth hormone-releasing peptides derived from ipamorelin. J. Med. Chem. (1998) 41:3699-3704.
94. NAGAMINE J, NAGATA R, SEKI H et al.: Pharmacological profile of a new orally active growth hormone secretagogue, SM-130686. J. Endocrinol. (2001) 171:481-489.
95. TOKUNAGA T, HUME WE, UMEZOME T et al.: Oxindole derivatives as orally active potent growth hormone secretagogues. J. Med. Chem. (2001) 44:4641-4649.
96. BEDNAREK MA, FEIGHNER SD, PONG S-S et al.: Structure-function studies on the new growth hormone-releasing peptide, ghrelin: minimal sequence of ghrelin necessary for activation of growth hormone secretagogue receptor 1a. J. Med. Chem. (2000) 43:4370-4376.
97. MATSUMOTO M, HOSODA H, KITAJIMA Y et al.: Structure-activity relationship of ghrelin: pharmacological study of ghrelin peptides. Biochem. Biophys. Res. Commun. (2001) 287:142-146.
98. TORSELLO A, GHE C, BRESCIANI E et al.: Short ghrelin peptides neither displace ghrelin binding in vitro nor stimulate GH release in vivo. Endocrinology (2002) 143:1968-1971.
99. PALUCKI BL, FEIGHNER SD, PONG S-S et al.: Spiro(indoline-3,4′-piperidine) growth hormone secretagogues as ghrelin mimetics. Bioorg. Med. Chem. Lett. (2001) 11:1955-1957.
100. SMITH RG, GRIFFIN PR, XU Y et al.: Adenosine: a partial agonist of the growth hormone secretagogue receptor. Biochem. Biophys. Res. Commun. (2000) 276:1306-1313.
101. TULLIN S, HANSEN BS, ANKERSEN M et al.: Adenosine is an agonist of the growth hormone secretagogue receptor. Endocrinology (2000) 141:3397-3402.
102. CHENG K, WEI L, CHAUNG L-Y et al.: Inhibition of L-692,429-stimulated rat growth hormone release by a weak substance P antagonist:L-756,867. J. Endocrinol. (1997) 152:155-158.
103. CHENG K, CHAN WWS, BUTLER B, WEI L, SMITH RG: A novel non-peptidyl growth hormone secretagogue. Horm. Res. (1993) 40:109-115.
104. SHUTO Y, SHIBASAKI T, OTAGIRI A et al.: Hypothalamic growth hormone secretagogue receptor regulates growth hormone secretion, feeding, and adiposity. J. Clin. Invest. (2002) 109:1429-1436.